

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Seth D. Cohen, MD

eRA COMMONS USER NAME (credential, e.g., agency login): huntmc1

POSITION TITLE: Hematology Oncologist

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Tochnit Torat Yerushalayim, Jerusalem, Israel	BA	05/1991	Biology
Yeshiva University, New York City, NY	BA	05/1994	Biology
S.U.N.Y. at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY	MD	06/1998	Medicine
Residency, UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ		06/2001	Internal Medicine
Fellowship, Fox Chase/Temple University Cancer Center, Philadelphia, PA 19111		06/2004	Hematology Oncology

**A. Personal Statement**

Dr. Seth D. Cohen is a board-certified internal medicine physician and medical oncologist. He holds the newly created position of Regional Director of Oncology Services for the RWJBarnabas Health Southern Region. In this role, Dr. Cohen will provide leadership and direction to enhance the quality and future growth of cancer services across Monmouth and Ocean counties, including integrating services available at Monmouth Medical Center, Monmouth Medical Center Southern Campus, and Community Medical Center. Prior to accepting this position, Dr. Cohen served as the Medical Director for Oncology Clinical Research at Monmouth Medical Center and Monmouth Medical Center Southern Campus and remains the principal investigator for several oncology clinical trials. As Regional Director of Oncology Services for the Southern Region, Dr. Cohen will utilize his clinical trials expertise to build and integrate an oncology clinical research program for the entire Southern Region. Dr. Cohen's new role as Regional Director of Oncology Services for the Southern Region, exemplifies our commitment to integrate, expand and enhance cancer services across the region for the people we serve throughout our communities. A member of the RWJBarnabas Health Medical Group, Dr. Cohen specializes in breast, colorectal and lung cancers; lymphomas; and genitourinary and gynecologic malignancies. He serves as an attending physician and is a member of the multidisciplinary team at the Jacqueline M. Wilentz Comprehensive Breast Center at Monmouth Medical Center and Monmouth Medical Center Southern Campus. Dr. Cohen is fellowship-trained in hematology and oncology with a subspecialty in pain and palliative care and has been affiliated with Monmouth Medical Center since 2004. Dr. Cohen received his medical degree from SUNY at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, completed his residency at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and completed his fellowship at Fox Chase Cancer Center in Philadelphia.

Ongoing and recently research projects that I would like to highlight include:

1. Open Label Non-Comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma.
2. Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Virus Adjuvant Hormonal Therapy Alone- (TAILORx Trial).

3. CALGB 90401: A Phase III trial comparing Docetaxel and Prednisone with or without Bevacizumab in men with hormone refractory Prostate Cancer.
4. ECOG E2805: A randomized double-blind Phase III trial of adjuvant Sunitinib versus Sorafenib versus Placebo with resected renal cell carcinoma.
5. PTH 320: An open label Phase II trial of Talabostat and Gemcitabine in patients with Stage IV Adenocarcinoma of the Pancreas.
6. GOG128: A phase III trial comparing Carboplatin and Paclitaxel with or without Bevacizumab and extended schedule in woman with Stage IV epithelial ovarian cancer.
7. IBCSG 24-02 (Soft Trial): A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer
8. E5204: Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin Vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation

## **B. Positions, Scientific Appointments, and Honors**

### **Positions and Scientific Appointments**

2020-Present	Regional Director of Oncology, Monmouth Medical Center, Long Branch, NJ
2020-Present Lakewood, NJ	Regional Director of Oncology, Monmouth Medical Center, Southern Campus,
2020-Present	Regional Director of Oncology, Community Medical Center, Toms River, NJ
2012-Present Branch, NJ	Medical Director of Oncology Clinical Research, Monmouth Medical Center, Long
2007-Present Branch, NJ	Chief Executive Officer, Monmouth Hematology Oncology Associates, P.A., West Long
2004-Present	Medical Physician Attending, Monmouth Medical Center, Long Branch, NJ
2004-Present Branch, NJ	Medical Oncologist, Monmouth Hematology Oncology Associates, P.A., West Long
2001-2002	Clinical Instructor of Medicine, Temple University Hospital, Philadelphia, PA
2000-2001	House Physician, St. Peter's University Hospital, New Brunswick, NJ

### **Other Experience and Professional Memberships**

ACP-ABIM- associate member  
 American Society of Hematology  
 American Society of Clinical Oncology

### **Honors**

2017, 2012, 2007	Best Doctors, New Jersey Monthly
2004, 2003	Amgen Fellow, Fox Chase Cancer Center, Philadelphia, PA
1996, 1995	Honors Microbiology, S.U.N.Y at Buffalo
1996, 1995	Dean's Letter of Commendation, S.U.N.Y at Buffalo
1994	Magna cum laude, Yeshiva University
1990	Israel Goldblum Scholar, Jerusalem, Israel

## **C. Contributions to Science**

1. At Rutgers Cancer Institute of New Jersey, the Overall Goals of the Clinical Investigations and Precision Therapeutics (CIPT) Program are to 1) translate outstanding science across the Cancer Center into early phase trials, 2) develop novel diagnostic, prevention, and therapeutic strategies; and 3) promote bidirectional translation from bench to bedside and

back. These goals are supported by close collaborations with the Cancer Metabolism and Immunology (CMI), Genome Instability and Cancer Genetics (GICG), and Cancer Pharmacology (CP) Programs. Translation of population science is done in collaboration with the Cancer Prevention and Control (CPC) Program.

2. Below are a few of the publications and abstracts that Dr. Seth D. Cohen has published for his research work through the years in field of cancer research. He has published over

Citations:

- a. Levy, M. Cohen, and S. Sedation for the Relief of Refractory Symptoms in the Imminently Dying: A Fine Intentional Line. *Seminars in Oncology*. 32: 237-246.
- b. Hue, K. Cohen, S. and Bechhofer, D. A Polypurine Sequence that Acts as a 5' mRNA Stabilizer in *Bacillus Subtilis*. *Journal of Bacteriology*. 1995; 177 (12) 3465-71.

3. Below are the abstracts that support Dr. Seth D. Cohen clinical research.

Abstracts:

- a. Cohen S, Schilder R, Padavic-Shaller K, Entmacher M, Rogatko A, Millenson M, Smith, M. Dexamethasone and 13-cis-retinoic acid for Untreated Multiple Myeloma. *ASH Proceedings* 2003
- b. Aisner, J, Goodin, Rafi, Cohen S., Ocasio, Colterelli, Todd, DiPoala, R. A Phase II Trial of 13-Cis-Retinoic Acid, Alpha Interferon, and Paclitaxel in Patients with Advanced Renal Cell Carcinoma. *ASCO Proceedings*, 2000.
- c. Goodin, Rafi, Cohen S., Ocasio, Aisner, DiPoala. A Phase II Trial of Cis-Retinoic Acid, Alpha-Interferon, and Paclitaxel in Patients with Advanced Prostate Cancer. *ASCO Proceedings* 2000.